N/A N=32 Online Education and Gentle Exercise Intervention
Chronic Pain · Pain
Primary: Brief Pain Inventory — 0.23; -0.29; -1.38; -1.32 Change in score of units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=20 An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
Melanoma · Skin Cancer
Primary: Number of Participants Experiencing Adverse Events — 0; 0; 3; 3 Participants
N/A N=221 Northern-Manhattan Hispanic Caregiver Intervention Effectiveness Study
Depressive Symptoms · Burden
Primary: Score on Geriatric Depression Scale — 9.57; 9.80 units on a scale — p=0.70
Phase 2 N=21 A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease
Alzheimer Disease
Primary: Treatment Related Adverse Events — 6; 3 Participants
N/A N=53 Cooking as a Health Behavior in College Students
Diet, Healthy
Primary: Diet Quality at Baseline and Change From Baseline — 65.11; 61.84; 61.08; 67.84 score on a scale — p=0.91
Phase 3 N=357 Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine
Migraine
Primary: Mean Change From Baseline in the Monthly (28 Days) Average Number of Migraine Days During the 12-week Period After the First Dose of Investigational Medicinal Product…
Phase 3 N=27 Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus
Left Ventricular Thrombosis
Primary: Percent Change in Left Ventricular Thrombus (LVT) Size — -61.45; -65.08 percentage of change
Phase 2 N=49 Consultation, Advice, and Tailored Support (CATS) for Cancer Survivors
Smoking Cessation · Social Stress
Primary: Accrual Percentage — 8.9 percentage of participants enrolled
Phase 2 N=251 Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.
Atopic Dermatitis
Primary: Change From Baseline (Week 0) to Week 8 in Eczema Area and Severity Index (EASI) Score. — -5.0; -4.9; -5.8; -7.6 score on a scale — p=<0.0001
N/A N=20 Remediation of Auditory Recognition in Schizophrenia With tDCS
Schizophrenia · Schizoaffective Disorder
Primary: Auditory Tone Matching Task — -4.3; 4.8 %correct, different trials
N/A N=78 Internet-Based Motivational Interviewing for Colonoscopy
Colorectal Neoplasms
Primary: Number of Participants Who Completed a Screening Colonoscopy — 19; 19 Participants
N/A N=102 Intervention to Enhance Lateral Balance Function and Prevent Falls in Aging
Accidental Falls
Primary: Hip Abductor Torque — 0.49; 0.49; 0.59; 0.0523 Nm/kg-m
Phase 2 N=8 Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in 4 Week Target Plaque Severity Score x Target Plaque Area in Cohort 2 — -66.6; -66.0; -38.1 Percent change — p=0.0007
Phase 2 N=32 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Prostate Cancer
Primary: Immune Responses to Treatment With Sipuleucel-T (With or Without Radium-223) Measured by Peripheral PA2024 T-cell Proliferation — 7.0; 22.4 fold change
Phase 1 N=39 A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants
Healthy Japanese Participants
Primary: Maximum Plasma Concentration (Cmax) of a Single Dose Padsevonil — 1029; 833.6; 721.3 ng/mL